FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:								

Instruc	tion 1(b).			File		uant to Section 16(Section 30(h) of the					f 1934		Tiodis ;	эст георопос.		
1. Name and Address of Reporting Person* PATRICK GREGORY S					2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]							eck all applio Directo	cable) or (give title	p Person(s) to Iss 10% Ov Other (s	wner	
	t) (First) (Middle)) SUPERNUS PHARMACEUTICALS, INC. 5 KEY WEST AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 05/20/2020							Sr.VP, Chief Financial Officer				
	ROCKVILLE MD 20850					4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																
		Tak	ole I - N	Non-Deriv	ative	Securities A	cquire	ed, D	isposed o	f, or B	eneficial	y Owned	l			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Followin Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
						Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)		(Instr. 4)		
Common Stock			05/20/2020			M ⁽¹⁾		15,000	A	\$12.98	61	,057	D			
Common Stock		05/20/2020			S ⁽¹⁾		15,000	D	\$25.0253	(2) 46	,057	D				
			Table			Securities Acc						Owned				
1. Title of Derivative Security	itle of 2. 3. Transaction 3A. Deemed 4 Execution Date 2.				5. Number of of the (Instr. Derivative		e Exer		7. Title a		8. Price of Derivative Security	erivative derivative		11. Nature of Indirect		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Acquir (A) or Dispos		ivative urities uired or oosed O) (Instr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (Right to Buy)	\$12.98	05/20/2020		M ⁽¹⁾			15,000	(3)	03/01/2026	Common Stock	15,000	\$0	35,000	D		

Explanation of Responses:

- 1. Transaction made pursuant to a 10b5-1 trading plan adopted November 26, 2019.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$25,0000 to \$25,1700, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- 3. The option vests in four equal annual installments beginning on March 1, 2017.

/s/ Gregory S. Patrick 05/20/2020

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.